Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications.
about
Neuronal networks in mental diseases and neuropathic pain: Beyond brain derived neurotrophic factor and collapsin response mediator proteinsProteomic and Microscopic Strategies towards the Analysis of the Cytoskeletal Networks in Major Neuropsychiatric DisordersMoving towards effective therapeutic strategies for Neuronal Ceroid LipofuscinosisAlternative functions of the brain transsulfuration pathway represent an underappreciated aspect of brain redox biochemistry with significant potential for therapeutic engagementThe Beta-amyloid protein of Alzheimer's disease: communication breakdown by modifying the neuronal cytoskeletonSpecific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamideA Tale of the Good and Bad: Remodeling of the Microtubule Network in the Brain by Cdk5A cell-penetrating ester of the neural metabolite lanthionine ketimine stimulates autophagy through the mTORC1 pathway: Evidence for a mechanism of action with pharmacological implications for neurodegenerative pathologiesALS as a distal axonopathy: molecular mechanisms affecting neuromuscular junction stability in the presymptomatic stages of the diseaseCdk5-FOXO3a axis: initially neuroprotective, eventually neurodegenerative in Alzheimer's disease modelsSub-Chronic Neuropathological and Biochemical Changes in Mouse Visual System after Repetitive Mild Traumatic Brain InjurySirt1 promotes axonogenesis by deacetylation of Akt and inactivation of GSK3Collapsin response mediator protein 2: high-resolution crystal structure sheds light on small-molecule binding, post-translational modifications, and conformational flexibility.Use of lacosamide in children with refractory epilepsyNitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines.Analysis of the rat hypothalamus proteome by data-independent label-free LC-MS/MS.Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder.Neuroprotective Effect of Lacosamide on Hypoxic-Ischemic Brain Injury in Neonatal Rats.Discovery of new membrane-associated proteins overexpressed in small-cell lung cancer.The functionalized amino acid (S)-Lacosamide subverts CRMP2-mediated tubulin polymerization to prevent constitutive and activity-dependent increase in neurite outgrowthCollapsin response mediator proteins regulate neuronal development and plasticity by switching their phosphorylation status.Phospholipase D signaling pathways and phosphatidic acid as therapeutic targets in cancerA PEPTIDE UNCOUPLING CRMP-2 FROM THE PRESYNAPTIC Ca(2+) CHANNEL COMPLEX DEMONSTRATES EFFICACY IN ANIMAL MODELS OF MIGRAINE AND AIDS THERAPY-INDUCED NEUROPATHY.PACAP38 differentially effects genes and CRMP2 protein expression in ischemic core and penumbra regions of permanent middle cerebral artery occlusion model mice brain.Role for NUP62 depletion and PYK2 redistribution in dendritic retraction resulting from chronic stressProgress in therapy development for amyotrophic lateral sclerosisIdentification of a dithiol-disulfide switch in collapsin response mediator protein 2 (CRMP2) that is toggled in a model of neuronal differentiationIsoaspartate accumulation in mouse brain is associated with altered patterns of protein phosphorylation and acetylation, some of which are highly sex-dependent.Identification of a proline-rich inositol polyphosphate 5-phosphatase (PIPP)•collapsin response mediator protein 2 (CRMP2) complex that regulates neurite elongation.Silencing collapsin response mediator protein-2 reprograms macrophage phenotype and improves infarct healing in experimental myocardial infarction modelNeuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein 2 (CRMP2)Vertebrate-specific glutaredoxin is essential for brain development.A collapsin response mediator protein 2 isoform controls myosin II-mediated cell migration and matrix assembly by trapping ROCK II.Disruption of NMDAR-CRMP-2 signaling protects against focal cerebral ischemic damage in the rat middle cerebral artery occlusion modelPooled genome wide association detects association upstream of FCRL3 with Graves' disease.Expression of a Mutant SEMA3A Protein with Diminished Signalling Capacity Does Not Alter ALS-Related Motor Decline, or Confer Changes in NMJ Plasticity after BotoxA-Induced Paralysis of Male Gastrocnemic MusclePhosphoproteomic differences in major depressive disorder postmortem brains indicate effects on synaptic function.A derivative of the CRMP2 binding compound lanthionine ketimine provides neuroprotection in a mouse model of cerebral ischemia.Proteomic, genomic and translational approaches identify CRMP1 for a role in schizophrenia and its underlying traits.Opening Pandora's jar: a primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neuron, and central disorders.
P2860
Q26750915-7EDBDF39-C2BA-4296-BB37-E065235E34F5Q26750966-2D91627C-69F9-4611-B0A6-5E19EB2BCF1CQ26753109-3982BCBD-CD86-459B-9AB6-EB9FE57F2301Q26851534-5BBF53AC-BC02-4C68-B6ED-690F5B2AAC90Q26864818-A81BDC75-03F4-424F-87FB-FF0011D99224Q27014744-9FB54D37-D873-45A4-A485-543EED3D9474Q28388637-6D90DC8E-BF27-4BF8-850B-6489353B1874Q28388679-019196AB-B8EA-46D2-B412-8F4CAEE385C3Q28392297-62443832-8FBC-458F-89CC-9DA4E9C4640EQ28396052-6D3D3E67-76EF-4858-A166-9F3518ED2037Q28551414-2E441CA0-B819-4BE6-AE74-BE47419B72F4Q28570544-5B2B4DC4-9547-460F-85A8-9F98389CBE89Q30396999-5ACCADBD-F089-4FF6-9851-6B4F901ADEE8Q30423294-C4307C65-E21F-4383-A8A5-2528B9C72CE4Q30431810-15FEAC5A-3B2D-467D-8CD6-390DA4BFD7B7Q30569671-1382D7F5-5458-49B1-8340-76BCBE579D8FQ30801268-9D0CEE59-D854-47EF-ACEB-0BAB3E6874F6Q33567241-2A36DB27-3321-4A2E-806A-428FF199AAC1Q33640246-01880103-F979-4473-900A-7E0D8B6882F6Q33944532-BA8E4FFC-5D3A-4C22-8F91-7AF0E3E4E4C7Q34255835-538A85E1-3C67-4907-8041-FECCD1971853Q34268347-EFEF9A65-1805-47C4-924D-00F6CB981356Q34291550-7ADE2623-CBFF-4AEA-AC34-3AC56A0563C3Q34358768-E53B3124-F457-49FC-BB6E-6E0B46BAFBAFQ34525933-83FEF092-B66C-4697-B6E3-5CF9DB4E263BQ34640800-708AF90A-75F3-48FF-AFCE-AF200ACE86E6Q35019524-062B3B39-1DD3-42FA-8CF6-D3BEFBE88F96Q35041665-09338B9A-4ED2-4EC1-91C3-13D5B808BECEQ35067846-19216C0D-290C-4639-A015-71FAF9E83140Q35083493-7E929364-D5C6-4CFA-A472-F3F2C50A0529Q35424151-08603ADE-31ED-4876-822F-B28E515E16CAQ35651372-05CA5053-5F51-44ED-B6C6-D70C883496A4Q35943914-7008EF38-C773-4431-B5B6-CF7159E071EAQ36009624-CB0CAFCB-8A2A-4C3F-9078-B1844D213150Q36198104-42E2055C-A0AA-46C6-96D6-0D49428D8B37Q36254139-2F119DED-DC20-4B97-94E6-4FD8696C6DA6Q36377477-BBF76FF1-4409-40C8-9BC8-A3218978BE2EQ36442837-B5AB3ED9-D6AC-4B2E-8222-FB936B423FA1Q36486743-D43A1425-8C03-437A-B099-37298A8D6D5AQ36517220-2865617B-DF46-464C-8418-B51627E91C02
P2860
Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Collapsin response mediator pr ...... for neurodisease indications.
@en
Collapsin response mediator pr ...... for neurodisease indications.
@nl
type
label
Collapsin response mediator pr ...... for neurodisease indications.
@en
Collapsin response mediator pr ...... for neurodisease indications.
@nl
prefLabel
Collapsin response mediator pr ...... for neurodisease indications.
@en
Collapsin response mediator pr ...... for neurodisease indications.
@nl
P2093
P2860
P1476
Collapsin response mediator pr ...... for neurodisease indications.
@en
P2093
Alexandar Christov
Joshua Park
Kenneth Hensley
William Gunning
P2860
P2888
P304
P356
10.1007/S12035-011-8166-4
P577
2011-01-28T00:00:00Z